{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:00:52Z","timestamp":1792533652544,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs are at high risk of venous thromboembolism (VTE), but data are lacking from large prospective cohorts. We present thrombosis outcome data from Myeloma IX (n = 1936) and Myeloma XI (n = 4358) phase 3 randomized controlled trials for NDMM that treated transplant-eligible and transplant-ineligible patients before and after publication of thrombosis prevention guidelines. In Myeloma IX, transplant-eligible patients randomly assigned to cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) induction had higher risk of VTE compared with patients treated with cyclophosphamide, thalidomide, and dexamethasone (CTD) (22.5% [n = 121 of 538] vs 16.1% [n = 89 of 554]; adjusted hazard ratio [aHR],1.46; 95% confidence interval [95% CI], 1.11-1.93). For transplant-ineligible patients, those randomly assigned to attenuated CTD (CTDa) induction had a higher risk of VTE compared with those treated with melphalan and prednisolone (MP) (16.0% [n = 68 of 425] vs 4.1% [n = 17 of 419]; aHR, 4.25; 95% CI, 2.50-7.20). In Myeloma XI, there was no difference in risk of VTE (12.2% [n = 124 of 1014] vs 13.2% [n = 133 of 1008]; aHR, 0.92; 95% CI, 0.72-1.18) or arterial thrombosis (1.2% [n = 12 of 1014] vs 1.5% [n = 15 of 1008]; aHR, 0.80; 95% CI, 0.37-1.70) between transplant-eligible pathways for patients treated with cyclophosphamide, lenalidomide, and dexamethasone (CRD) or CTD. For transplant-ineligible patients, there was no difference in VTEs between attenuated CRD (CRDa) and CTDa (10.4% [n = 95 of 916] vs 10.7% [n = 97 of 910]; aHR, 0.97; 95% CI, 0.73-1.29). However, arterial risk was higher with CRDa than with CTDa (3.1% [n = 28 of 916] vs 1.6% [n = 15 of 910]; aHR, 1.91; 95% CI, 1.02-3.57). Thrombotic events occurred almost entirely within 6 months of treatment initiation. Thrombosis was not associated with inferior progression-free survival (PFS) or overall survival (OS), apart from inferior OS for patients with arterial events (aHR, 1.53; 95% CI, 1.12-2.08) in Myeloma XI. The Myeloma XI trial protocol incorporated International Myeloma Working Group (IMWG) thrombosis prevention recommendations and compared with Myeloma IX, more patients received thromboprophylaxis (80.5% vs 22.3%) with lower rates of VTE for identical regimens (CTD, 13.2% vs 16.1%; CTDa, 10.7% vs 16.0%). However, thrombosis remained frequent in spite of IMWG-guided thromboprophylaxis, suggesting that new approaches are needed.<\/jats:p>","DOI":"10.1182\/blood.2020005125","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T22:57:12Z","timestamp":1590101832000},"page":"1091-1104","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials"],"prefix":"10.1182","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-8165","authenticated-orcid":false,"given":"Charlotte A.","family":"Bradbury","sequence":"first","affiliation":[{"name":"School of Translational Health Sciences, University of Bristol, Bristol, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-6648","authenticated-orcid":false,"given":"Zoe","family":"Craig","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-0412","authenticated-orcid":false,"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;"},{"name":"Leeds Cancer Centre, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, United Kingdom;"},{"name":"The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-0179","authenticated-orcid":false,"given":"David A.","family":"Cairns","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hockaday","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Paterson","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0216-7464","authenticated-orcid":false,"given":"Matthew W.","family":"Jenner","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Jones","sequence":"additional","affiliation":[{"name":"Kings College Hospital NHS Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Drayson","sequence":"additional","affiliation":[{"name":"Clinical Immunology, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Owen","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, St James\u2019s University Hospital, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin F.","family":"Kaiser","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research, London, United Kingdom;"},{"name":"The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Gregory","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, New York University Langone Health, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Anthony","family":"Child","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Perlmutter Cancer Center, New York University Langone Health, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham H.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Freeman Hospital, University of Newcastle, Newcastle Upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2020092415340821800_B1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2020092415340821800_B2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12957-015-0592-8","article-title":"Venous thromboembolism in cancer patients: an underestimated major health problem","volume":"13","author":"Khalil","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"1","key":"2020092415340821800_B3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/bjhp.12213","article-title":"\u201cPost-thrombotic panic syndrome\u201d: A thematic analysis of the experience of venous thromboembolism","volume":"22","author":"Hunter","year":"2017","journal-title":"Br J Health Psychol"},{"issue":"1","key":"2020092415340821800_B4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"issue":"2","key":"2020092415340821800_B5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","article-title":"Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias","volume":"145","author":"Eby","year":"2009","journal-title":"Br J Haematol"},{"issue":"29","key":"2020092415340821800_B6","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1200\/JCO.2009.22.8197","article-title":"Venous thromboembolism in the hematologic malignancies","volume":"27","author":"Falanga","year":"2009","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020092415340821800_B7","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"2020092415340821800_B8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8051","article-title":"Association of venous thromboembolism with increased mortality in patients with multiple myeloma [abstract]","volume":"36","author":"Schoen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020092415340821800_B9","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2020092415340821800_B10","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"2020092415340821800_B11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2020092415340821800_B12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"2020092415340821800_B13","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1002\/ajh.25658","article-title":"Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score","volume":"95","author":"Chalayer","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"2020092415340821800_B14","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"2020092415340821800_B15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"2020092415340821800_B16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020092415340821800_B17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2020092415340821800_B18","first-page":"844","article-title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","volume":"110","author":"Leleu","year":"2013","journal-title":"Thromb Haemost"},{"issue":"12","key":"2020092415340821800_B19","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"13","key":"2020092415340821800_B20","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2020092415340821800_B21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"issue":"28","key":"2020092415340821800_B22","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA\u2013Italian Multiple Myeloma Network","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020092415340821800_B23","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann Oncol"},{"key":"2020092415340821800_B24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","article-title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review","volume":"141","author":"Al-Ani","year":"2016","journal-title":"Thromb Res"},{"key":"2020092415340821800_B25","article-title":"Aspirin may be inadequate thromboprophylaxis in multiple myeloma [abstract]","volume":"130","author":"Sanfilippo","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020092415340821800_B26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11239-019-01891-0","article-title":"What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial","volume":"48","author":"Sayar","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2020092415340821800_B27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2020092415340821800_B28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjh.15392","article-title":"Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens","volume":"185","author":"Storrar","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2020092415340821800_B29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","article-title":"Guidelines for the diagnosis and management of multiple myeloma 2011","volume":"154","author":"Bird","year":"2011","journal-title":"Br J Haematol"},{"key":"2020092415340821800_B30","unstructured":"National Institute for Health and Care Excellence\n          . Myeloma: diagnosis and management. NICE guideline [NG35]. 2016. Available at: https:\/\/www.nice.org.uk\/guidance\/ng35. Accessed 30 January 2020."},{"issue":"3","key":"2020092415340821800_B31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3324\/haematol.2011.043372","article-title":"Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results","volume":"97","author":"Morgan","year":"2012","journal-title":"Haematologica"},{"issue":"5","key":"2020092415340821800_B32","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2020092415340821800_B33","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2020092415340821800_B34","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"2020092415340821800_B35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020092415340821800_B36","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2020092415340821800_B37","first-page":"255","article-title":"Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer","volume":"112","author":"Martinez","year":"2014","journal-title":"Thromb Haemost"},{"issue":"1","key":"2020092415340821800_B38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-019-03860-2","article-title":"The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma","volume":"99","author":"Li","year":"2020","journal-title":"Ann Hematol"},{"issue":"1","key":"2020092415340821800_B39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2020092415340821800_B40","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"}],"updated-by":[{"DOI":"10.1182\/blood.2020009029","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/9\/1091\/1759266\/bloodbld2020005125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/136\/9\/1091\/1759266\/bloodbld2020005125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T19:35:39Z","timestamp":1600976139000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/136\/9\/1091\/456042\/Thrombosis-in-patients-with-myeloma-treated-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020005125","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/blood.2020009029","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]}}}